## FRONTIERS OF SCIENCE THE Developing New Possibilities for Patients 

Today we stand on the frontiers of extraordinary new possibilities for addressing significant unmet medical need. And while we have come a great distance in the past several years to successfully transform ourselves into a benchmark BioPharma company, there are great opportunities to do even more. Most importantly, we have and will continue to attract and retain the best people around the world. And each day they come to work, they remain committed to a single overriding mission: to help more patients prevail in their fight against serious diseases. 

As we look to the future, we will need to focus our efforts across a number of essential areas: 

• Extending the Reach of Our Medi - cines – Ensuring that more patients around the world gain access to our leading medicines will help them prevail over their illnesses, create value for our shareholders and develop the resources required to invest in our future. 

• Ensuring a Robust R&D Pipeline – In addition to the diseases for which we have medicines already available, we continue to diversify and expand our horizons in areas like hepatitis C, neu- rodegenerative disorders and fibrosis. 

• Creating a Culture of Continuous Improvement  – Working smarter, better and faster will help us drive 

our competitive advantage to deliver the promise of new medicines. 

• Developing Innovations on the Frontiers of Medicine  – Cardiovas- cular disease, immuno-oncology and diabetes are three leading areas where we have recently introduced new medicines and where we are developing a pipeline of innovative therapies that expand the frontiers of biomedical research. 

• Committing to Responsible Citizen - ship  – Acting in a socially respon- sible, ethical and sustainable manner is a commitment we must make and act upon every day. 

In this Special Report, we examine each area and introduce you to exam- ples of how our people continue to transform Bristol-Myers Squibb and in so doing, help develop new possibilities for patients everywhere. 

